Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S241656 in Selected Myeloid Malignancies
NCT07719348Phase 2Not yet recruiting
- Sponsor
- Servier
- Start
- Sep 2026
- Primary completion
- Nov 2027
01
Overview
A Phase 2 trial of bdtx-4933 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Servier. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
bdtx-4933
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT07719348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719348.